0001213900-26-057842
SEC filingQ2 operating and net losses widened significantly year-over-year due to sharply higher operating expenses that outpaced revenue growth and gross profit gains from LYMPHIR launch, despite offsets from other income and tax benefits.
Citius Pharmaceuticals reported Q2 FY2026 revenue of $1.7 million, driven by early commercialization of LYMPHIR, a newly launched product showing initial market acceptance with repeat orders from accounts and Citius Oncology's first shipment to Europe on April 29, 2026. Gross profit reached $1.3 million, yielding an 80.3% margin, which reflects strong underlying product economics even as estimates for gross-to-net adjustments rely on distributor inventory, market data, and comparables pending sufficient historical data.
Looking forward, management anticipates revenue growth as LYMPHIR builds acceptance, supported by expected prescribing expansion and investigator-led studies at Citius Oncology. However, liquidity remains strained, with the need for additional capital beyond November 2026 to fund operations. General and administrative expenses include compensation, professional fees for legal, regulatory, accounting, and corporate development, plus investor relations—typical for a clinical-stage pharma navigating product launches. Inflation had no material impact on results.